Q Therapeutics of the United States and REPROCELL of Japan are teaming up to develop stem cell-based therapies for central nervous system diseases such as ALS and transverse myelitis, or TM.

The collaboration will meld Q Therapeutics’ expertise in nerve cell therapy with REPROCELL’s expertise in stem cell treatments.

“This collaboration with Q Therapeutics and their scientific co-founder, Dr. Mahendra Rao, enables us to accelerate our therapeutic regenerative medicine business using iPS [induced pluripotent stem] cells,” Dr. Chikafumi Yokoyama, the CEO of REPROCELL, said in a press release. “I am also honored to step into contributing to unmet medical needs like ALS and TM using our proprietary iPS cell technology.”

 

more at: https://alsnewstoday.com/2017/12/21/q-therapeutics-and-reprocell-collaborating-on-stem-cell-based-therapies-for-als/